Last $13.13 USD
Change Today +0.07 / 0.54%
Volume 1.8M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 Boston Scientific Way

Marlborough, MA 01752-1234

United States

Phone: 508-683-4000

Fax: 508-650-8923

Boston Scientific Corporation develops, manufactures, and markets medical devices that are used in a range of interventional medical specialties. Products During 2013, the company’s products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women’s Health, Neuromodulation, and Electrophysiology (EP). Cardiovascular Interventional Cardiology Coronary Stent Systems The company markets a portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. In addition, in Europe the company markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. In February 2013, the company received Conformite Europeenne (CE) Mark approval and, in 2013, Food and Drug Administration (FDA) clearance for its next-generation Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System. Core Coronary Technology The company markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease which is characterized by a thickening of the walls of the coronary arteries and a narrowing of arterial openings caused by the progressive development of deposits of plaque. The company’s product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures. Intraluminal Ultrasound Imaging The company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers as well as certain peripheral vessels. This system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Structural Heart Therapy The company develops a fully repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. The low-profile delivery system and introducer sheath are designed to enable accurate positioning, repositioning and retrieval at any time prior to release of the aortic valve implant. In the fourth quarter of 2013, the company received CE Mark approval and launched the Lotus Valve System in Europe. In 2011, the company acquired Atritech, Inc. (Atritech). Atritech developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation (AF) who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology (WATCHMAN LAA), developed by Atritech, is a device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries. Additionally in 2012, European regulators approved an expanded indication for the WATCHMAN LAA Closure Device. In 2013, the company submitted the results of the U.S. IDE trial, PREVAIL, to the FDA. Peripheral Interventions The company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. The company’s peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. The company’s peripheral angioplasty balloon technology includes its Mustang PTA balloon; its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures; and its Charger PTA Balloon Catheter, a 0.035’ percutaneous transluminal angioplasty balloon ca

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.13 USD +0.07

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $139.90 USD +1.44
CR Bard Inc $169.10 USD -0.44
Olympus Corp ¥4,445 JPY +10.00
St Jude Medical Inc $66.67 USD +0.67
Terumo Corp ¥2,846 JPY -27.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 61.3x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 24.2x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.